Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБОУ ВО «Приволжский исследовательский медицинский университет» Минздрава России, Нижний Новгород, Россия borovkov-nn@mail.ru
Список исп. литературыСкрыть список 1. Стабильная ишемическая болезнь сердца. Клинические рекомендации. Минздрав России. М., 2020. [Stabil'naia ishemicheskaia bolezn' serdtsa. Klinicheskie rekomendatsii. Minzdrav Rossii. Moscow, 2020 (in Russian).] 2. Острый инфаркт миокарда с подъемом сегмента ST на электрокардиограмме. Клинические рекомендации. Минздрав России. М., 2020. [Ostryi infarkt miokarda s pod"emom segmenta ST na elektrokardiogramme. Klinicheskie rekomendatsii. Minzdrav Rossii. Moscow, 2020 (in Russian).] 3. Фибрилляция и трепетание предсердий. Клинические рекомендации. Одобрено на заседании Научно-практического совета Минздравf России (заседание от 16.10.2020, протокол №38/2-3-4). М., 2020. [Fibrilliatsiia i trepetanie predserdii. Klinicheskie rekomendatsii. Odobreno na zasedanii Nauchno-prakticheskogo soveta Minzdravf Rossii (zasedanie ot 16.10.2020, protokol №38/2-3-4). Moscow, 2020 (in Russian).] 4. Eikelboom JW, Connolly SJ, Bosch J et al. COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377: 1319–30. DOI: 10.1056/NEJMoa1709118 5. Downloaded from https://academic.oup.com/europace/advance-article/doi/10.1093/europace/euab065/6247378 by guest on 01 May 2021. 6. Тарасова Л.В., Димитриева О.В., Бусалаева Е.И. Гастродуоденальные риски при терапии новыми оральными антикоагулянтами и возможности их минимизации. Медицинский алфавит. 2020 (13): 26–32. DOI: 10.33667/2078-5631-2020-13-26-32. [Tarasova L.V., Dimitrieva O.V., Busalaeva E.I. Gastroduodenal'nye riski pri terapii novymi oral'nymi antikoaguliantami i vozmozhnosti ikh minimizatsii. Meditsinskii alfavit. 2020 (13): 26–32. DOI: 10.33667/2078-5631-2020-13-26-32 (in Russian).] 7. Мороз Е.В., Каратеев А.Е., Крюков Е.В., Чернецов В.А. Желудочно-кишечные кровотечения при использовании новых пероральных антикоагулянтов: эпидемиология, факторы риска, лечение и профилактика. Научно-практическая ревматология. 2017; 55 (6): 675–84. [Moroz E.V., Karateev A.E., Kriukov E.V., Chernetsov V.A. Gastrointestinal bleeding with the use of new oral anticoagulants: epidemiology, risk factors, treatment, and prevention. Nauchno-prakticheskaia revmatologiia. 2017; 55 (6): 675–84 (in Russian).] 8. Hsu PI, Tsai TJ. Epidemiology of Upper Gastrointestinal Damage Associated with Low-Dose Aspirin. Curr Pharm Des 2015; 21 (35): 5049–55. DOI: 10.2174/1381612821666150915104800 9. Боровкова Н.Ю., Буянова М.В., Терехова В.В. и др. Особенности аспирининдуцированных поражений желудочно-кишечного тракта у больных хронической ишемической болезнью сердца и возможные пути их коррекции. Кардиоваскулярная терапия и профилактика. 2020; 19 (2): 2463. DOI: 10.15829/1728-8800-2020-2-2463 [Borovkova N.Iu., Buianova M.V., Terekhova V.V. et al. Osobennosti aspirinindutsirovannykh porazhenii zheludochno-kishechnogo trakta u bol'nykh khronicheskoi ishemicheskoi bolezn'iu serdtsa i vozmozhnye puti ikh korrektsii. Kardiovaskuliarnaia terapiia i profilaktika. 2020; 19 (2): 2463. DOI: 10.15829/1728-8800-2020-2-2463 (in Russian).] 10. Garcia Rodriguez LA, Martin-Perez M, Hennekens CH et al. Bleeding Risk with Long-Term LowDose Aspirin: A Systematic Review of Observational Studies. PLoS One 2016; 11 (8): e0160046. DOI: 10.1371/journal.pone.0160046 11. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin – what’s the risk? Aliment Pharmacol Ther 2006; 24: 897–908. DOI: 10.1111/j.1365-2036.2006.03077.x 12. Sorensen HT, Mellemkjaer L, Blot WJ et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000; 95: 2218–24. DOI: 10.1111/j.1572-0241.2000. 02248.x 13. Watari I, Oka S et al. Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study. BMC Gastroenterol 2013; 13: 108. DOI: 10.1186/1471-230X-13-108 14. Watari I, Oka S, Tanaka S et al. Comparison of small-bowel mucosal injury between low-dose aspirin and nonaspirin non-steroidal anti-Inflammatory drugs: a capsule endoscopy study. Digestion 2014; 89 (3): 225–31. 15. Endo H, Hosono K, Inamori M et al. Incidence of small bowel injury induced by low-dose aspirin: a crossover study using capsule endoscopy in healthy volunteers. Digestion 2009; 79 (1): 44–51. 16. Ушкалова Е.А. Клиническая фармакология современных антацидов. Фарматека. 2006; 126 (11): 24–31. [Ushkalova E.A. Klinicheskaia farmakologiia sovremennykh antatsidov. Farmateka. 2006; 126 (11): 24–31 (in Russian).] 17. Каратеев А.Е., Мороз Е.В. Проблема НПВП-гастропатии. Современные представления. Медицинский алфавит. 2017; 4 (40): 13–20. [Karateev A.E., Moroz E.V. Problema NPVP-gastropatii. Sovremennye predstavleniia. Meditsinskii alfavit. 2017; 4 (40): 13–20 (in Russian).] 18. Власова Т.В., Шкарин В.В., Соловьева Е.В. Кардиоваскулярные и гастроинтестинальные связи: прогностическая значимость коморбидного больного и др. Медицинский совет. 2017; 7: 98–101. [Vlasova T.V., Shkarin V.V., Solov'eva E.V. Kardiovaskuliarnye i gastrointestinal'nye sviazi: prognosticheskaia znachimost' v bol'nogo et al. Meditsinskii sovet. 2017; 7: 98–101 (in Russian).] 19. Пахомова И.Г., Хорошинина Л.П. Как минимизировать риски НПВП-индуцированных поражений ЖКТ? Возможная тактика ведения пациента. Медицинский алфавит. 2017; 1 (8): 15–23. [Pakhomova I.G., Khoroshinina L.P. Kak minimizirovat' riski NPVP-indutsirovannykh porazhenii ZhKT? Vozmozhnaia taktika vedeniia patsienta. Meditsinskii alfavit. 2017; 1 (8): 15–23 (in Russian).] 20. Watanabe T, Fujiwara Y, Chan Watanabe F et al. Current knowledge on non-steroidal anti-inflammatory druginduced small-bowel damage: a comprehensive review. J Gastroenterol 2019; 55: 105–10. DOI: 10.1007/s00535-019-01657-8 21. Ким В.А. НПВП-гастропатия и роль простагландинов в ее возникновении, профилактике и лечении. Экспериментальная и клиническая гастроэнтерология. 2008; 8: 84–91. [Kim V.A. NPVP-gastropatiia i rol' prostaglandinov v ee vozniknovenii, profilaktike i lechenii. Eksperimental'naia i klinicheskaia gastroenterologiia. 2008; 8: 84–91 (in Russian).] 22. Емелина Е.И. Кардиомагнил: улучшение приверженности к лечению за счет снижения частоты побочных эффектов. Атмосфера. Новости кардиологии. 2011; 1: 14–8. [Emelina E.I. Kardiomagnil: uluchshenie priverzhennosti k lecheniiu za schet snizheniia chastoty pobochnykh effektov. Atmosfera. Novosti kardiologii. 2011; 1: 14–8 (in Russian).] 23. Боровкова Н.Ю., Буянова М.В., Бакка Т.Е. и др. Возможности лечения аспирин-индуцированных поражений желудка и двенадцатиперстной кишки у пациентов с хронической ишемической болезнью сердца. Клиническая медицина. 2020; 98 (3): 231–35. DOI: 10.30629/0023-2149-2020-98-3-231-235 [Borovkova N.Iu., Buianova M.V., Bakka T.E. et al. Vozmozhnosti lecheniia aspirin-indutsirovannykh porazhenii zheludka i dvenadtsatiperstnoi kishki u patsientov s khronicheskoi ishemicheskoi bolezn'iu serdtsa. Klinicheskaia meditsina. 2020; 98 (3): 231–35. DOI: 10.30629/0023-2149-2020-98-3-231-235 (in Russian).] 24. Левых А.Э. Ацетилсалициловая кислота как эффективная и безопасная основа антиагрегантной терапии. Артериальная гипертензия. 2015; 44 (6): 57–63. [Levykh A.E. Atsetilsalitsilovaia kislota kak effektivnaia i bezopasnaia osnova antiagregantnoi terapii. Arterial'naia gipertenziia. 2015; 44 (6): 57–63 (in Russian).] 25. Пахомова И.Г. НПВП-ассоциированные повреждения желудочно-кишечного тракта и их осложнения: пути профилактики. Consilium Medicum. 2017; 19 (9): 109–13. [Pakhomova I.G. NPVP-assotsiirovannye povrezhdeniia zheludochno-kishechnogo trakta i ikh oslozhneniia: puti profilaktiki. Consilium Medicum. 2017; 19 (9): 109–13 (in Russian).] 26. Минушкина А.О. Проблемы безопасности при использовании препаратов ацетилсалициловой кислоты для профилактики сердечно-сосудистых осложнений. Сердце: журнал для практикующих врачей. 2014; 13 (3): 173–78. [Minushkina A.O. Problemy bezopasnosti pri ispol'zovanii preparatov atsetilsalitsilovoi kisloty dlia profilaktiki serdechno-sosudistykh oslozhnenii. Serdtse: zhurnal dlia praktikuiushchikh vrachei. 2014; 13 (3): 173–78 (in Russian).] 27. Ota K, Takeuchi T, Kojima Yet al. Preventive effect of ecabet sodium on low-dose aspirin-induced small intestinal mucosal injury: a randomized, double-blind, pilot study. BMC Gastroenterology 2019; 1. DOI: 10.1186/s12876-018-0923-7 28. Wallace JL. Prostaglandins NSAIDs and gastric mucosal protection: why doesn't the stomach digest itself? Physiolog Rev 2008; 88 (4): 1547–65. 29. Бабак С.В., Бакунин И.Г., Балукова Е.В. и др. Поражения органов пищеварения, индуцированные приемом нестероидных противовоспалительных препаратов. СПб.: ИнформМед, 2013. ISBN 978-5-904192-62-4 [Babak S.V., Bakunin I.G., Balukova E.V. et al. Porazheniia organov pishchevareniia, indutsirovannye priemom nesteroidnykh protivovospalitel'nykh preparatov. Saint Petersburg: InformMed, 2013. ISBN 978-5-904192-62-4 (in Russian).] 30. Маев И.В., Самсонов А.А., Андреев Д.Н. Болезни желудка: монография. М.: ГЭОТАР-Медиа, 2015. ISBN 978-5-9704-3388-1 [Maev I.V., Samsonov A.A., Andreev D.N. Bolezni zheludka: monografiia. Moscow: GEOTAR-Media, 2015. ISBN 978-5-9704-3388-1 (in Russian).] 31. Кляритская И.Л., Мошко Ю.А., Балабанцева А.П. и др. Патология гастродуоденальной зоны, индуцированная НПВП и терапевтическая тактика. Крымский терапевтический журнал. 2017; 1: 5–15. [Kliaritskaia I.L., Moshko Iu.A., Balabantseva A.P. et al. Patologiia gastroduodenal'noi zony, indutsirovannaia NPVP i terapevticheskaia taktika. Krymskii terapevticheskii zhurnal. 2017; 1: 5–15 (in Russian).] 32. Lip G, Keshishian A, Li X et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke 2018; 49 (12): 2933–44. 33. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–91. DOI: 10.1056/NEJMoa1009638 34. Sherwood MW, Nessel CC, Hellkamp AS et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF trial. J Am Coll Cardiol 2015; 66 (21): 2271–81. DOI: 10.1016/j.jacc.2015.09.024 35. Hindricks G et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020; ehaa612. DOI: 10.1093/eurheartj/ehaa612 36. Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007; 177 (4): 347–51. DOI: 10.1503/cmaj. 070186 37. Oakland K et al. Rebleeding and Mortality After Lower Gastrointestinal Bleeding in Patients Taking Antiplatelets or Anticoagulants. Clin Gastroenterol Hepatol 2019; 17 (7): 1276–84.e3. 38. Lopes RD, Heizer G, Aronson R et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med 2019; 380: 1509–24. . DOI: 10.1056/NEJMoa1817083 39. Henry DA, Dobson C. Turner Variability in the risk of major gastrointestinal complications from nonsteroidal anti-inflammatory drugs. Gastroenterology 1993; 105 (4): 1078–88. 40. Лазебник Л.Б., Бордин Д.С., Ткаченко Е.И. и др. Лекарственные гастроэнтеропатии (рекомендации по профилактике и лечению гастроэнтеропатий, индуцированных нестероидными противовоспалительными препаратами). Терапия. 2018; 20 (2): 18–33. [Lazebnik L.B., Bordin D.S., Tkachenko E.I. et al. Lekarstvennye gastroenteropatii (rekomendatsii po profilaktike i lecheniiu gastroenteropatii, indutsirovannykh nesteroidnymi protivovospalitel'nymi preparatami). Terapiia. 2018; 20 (2): 18–33 (in Russian).] 41. Endo H, Sakai E, Higurashi T et al. Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy. Dig Liver Dis 2012; 44 (10): 833–8. 42. Ушкалова Е.А. Аспиринорезистентность: механизмы развития, методы определения и клиническое значение. Фарматека. 2006; 128 (13): 35–41. [Ushkalova E.A. Aspirinorezistentnost': mekhanizmy razvitiia, metody opredeleniia i klinicheskoe znachenie. Farmateka. 2006; 128 (13): 35–41 (in Russian).] 43. Goodman LA. Gilman Goodman and Gilman`s the pharmacological basis of therapeutics. 8 ed. New York: Pergamon press, 1990: 1811 p. ISBN 0-08-040296-8 44. Bhatt D, Scheiman J, Abraham N et al. ACCF/ACG/AHA 2008 Expect consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use a report of the American college of cardiology foundation task force on clinical expert consensus documents. J Am College Cardiol 2008; 52 (18): 1502–17. 45. Taha AS, McCloskey C, Prasad R et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomized, double-blind, placebo-controlled trial. Lancet 2009; 374 (9684): 119–25. 46. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению эрозивно-язвенных поражений желудка, вызванных приемом нестероидных противовоспалительных препаратов. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2014; 6: 89–94. [Klinicheskie rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii po diagnostike i lecheniiu erozivno-iazvennykh porazhenii zheludka, vyzvannykh priemom nesteroidnykh protivovospalitel'nykh preparatov. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2014; 6: 89–94 (in Russian).] 47. Pozzoli C, Menozzi A, Grandi D et al. Protective effects of proton pump inhibitors against indomethacin-induced lesions in the rat small intestine. Naunyn Schmiedebergs Arch Pharmacol 2017; 374 (4): 283–91. DOI: 10.1007/s00210-006-0121-y 48. Мороз Е.В., Каратеев А.Е. Ребамипид: эффективная медикаментозная профилактика НПВП-энтеропатии возможна. Современная ревматология. 2016; 10 (4): 97–105. [Moroz E.V., Karateev A.E. Rebamipid: effektivnaia medikamentoznaia profilaktika NPVP-enteropatii vozmozhna. Sovremennaia revmatologiia. 2016; 10 (4): 97–105 (in Russian).] 49. Clooney AG, Bernstein CN, Leslie WD. A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Alimentary Pharmacol Therapeut 2016; 43 (9): 974–84. 50. Nadatani Y, Watanabe T, Suda W. Gastric acid inhibitor aggravates indomethacin-induced small intestinal injury via reducing Lactobacillus Johnsonii. Scientific Reports 2019: 17490. 51. Wallace J, Syer S, Denou E et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011; 141 (4): 1314–22. 52. Sostres С et al. Risk of rebleeding, vascular events and death after gastrointestinal bleeding in anticoagulant and/or antiplatelet users. Alimentary Pharmacol Terapeut 2019; 50 (8): 919–29. 53. Koch N. Non-steroidal anti-inflammatory drug gastropathy: clinical results with misoprostol. Ital J Gastroenterol Hepatol 1999; 31 (1): 54–62. 54. Silverstein FE., Graham DY, Senior JR.et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Annals Int Med 1995; 123 (4): 241–499. 55. Hawkey C, Karrasch J., Szczepanski L. et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. New England J Med 1998; 338 (11): 727–34. 56. Rostom A, Dube C, Wells G et al. Prevention of NSAID-induced gastroduodenal ulcers: review [art. № CD002296]. Cochrane Database Systematic Rev. 2002; 4. 57. Goldstein J, Huang B, Amer F et al. Ulcer recurrence in high-risk patients receiving nonsteroidal anti-inflammatory drugs plus low-dose aspirin: results of a post hoc subanalysis. Clin Therapeut 2004; 26 (10): 1637–43. 58. Park SH, Cho CS, Lee OY et al. Comparison of prevention of NSAIDinduced gastrointestinal complications by rebamipide and misoprostol: a randomized, multicenter, controlled trial-STORM STUDY. J Clin Biochem Nutr 2007; 40 (2): 148–55. DOI: 10.3164/jcbn.40.148 59. Becker J, Domschke W, Pohle T. Current approaches to prevent NSAID-induced gastropathy – COX selectivity and beyond. British J Clin Pharmacol 2004; 58 (6): 587–600. 60. Watanbe T, Sugimore S, Kameda N et al. Small bowel injury by low-dose entericcoated aspirin and treatment with misoptostol: a pilot study. Clin Gastroenterol Hepatol 2008; 6 (11): 1279–82. DOI: 10.1016/j.cgh.2008.06.021 61. Kohata Y, Nakahara K, Tanigawa T et al. Rebamipide alters the esophageal microbiome and reduces the incidence of Barrett's esophagus in a rat model. Dig Dis Sci 2015; 60 (9): 2654–61. DOI: 10.1007/s10620-015-3662-4 62. Moon SJ, Park JS, Woo YJ et al. Rebamipide suppresses collagen-induced arthritis through reciprocal regulation of th17/treg cell differentiation and hemeoxygenase 1 induction. Arthritis Rheumatol 2014; 66 (4): 874–85. DOI: 10.1002/art.38310 63. Звяглова М.Ю., Князев О.В., Парфенов А.И. Фармакологический и клинический профиль ребамипида: новые терапевтические мишени. Терапевтический архив. 2020; 92 (2): 104–11. [Zvyaglova M.Yu., Knyazev O.V., Parfenov A.I. Pharmacological and clinical feature of rebamipide: new therapeutic targets. Therapeutic Archive. 2020; 92 (2): 104–11. (in Russian).] 64. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol 2010; 4 (3): 261–70. DOI: 10.1586/egh.10.25 65. Kinjo N, Kawanaka H, Akahoshi T et al. Significance of ERK nitration in portal hypertensive gastropathy and its therapeutic implications. Amn J Physiol Gastrointestinal Liver Physiology 2008; 295 (5): G1016–G1024. 66. Abe N, Funato H, Hirata A. Evaluation of gastric mucosal injury model animals of rebamipide formulationstudy of therapeutic equivalence. Yakugaku Zasshi 2016; 136 (4): 677–84. 67. Hayashi S, Sugiyama T, Amano K et al. Effect of rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells. Antimicrobial Agents Chemotherapy 1998; 42 (8): 1895–99. 68. Nishizawa T, Nishizawa Y, Yahagi N et al. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: a systematic review and meta-analysis. J Gastroenterol Hepatol 2014; 29 (4): 20–4. 69. Li W, Zhao Y, Xu X et al. Rebamipide suppresses TNF-α mediated inflammation in vitro and attenuates the severity of dermatitis in mice. FEBS J 2015; 282 (12): 2317–26. DOI: 10.1111/febs.13278 70. Iijima K, Ichikawa T, Okada S et al. Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test. Digestive Diseases Sci 2009; 54 (7): 1500–7. 71. Akagi S, Fujiwara T, Nishida M et al. The effectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. J Pharm Health Care Sci 2019; 5: 16. DOI: 10.1186/s40780-019-0146-2 72. Tomita T, Sadakata T, Tamura M et al. Indomethacin-induced generation of reactive oxygen species leads to epithelial cell injury before the formation of intestinal lesions in mice. J Physiol Pharmacol 2014; 65 (3): 435–40. 73. Kurata S, Nakashima T, Osaki T et al. Rebamipide protects small intestinal mucosal injuries caused by indomethacin by modulating intestinal microbiota and the gene expression in intestinal mucosa in a rat model. J Clin Biochem Utrition 2015; 56 (1): 20–7. 74. Zhang S, Qing Q, Bai Y et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Diseases Scien 2013; 58 (7): 1991–2000. 75. Казюлин А.Н. Гончаренко А.Ю., Мамаев И.В. Использование ребамипида в качестве гастропротективного и противовоспалительного препарата при НПВП-гастропатиях. Лечебное дело. 2016; 3: 50–8. [Kaziulin A.N. Goncharenko A.Iu., Mamaev I.V. Ispol'zovanie rebamipida v kachestve gastroprotektivnogo i protivovospalitel'nogo preparata pri NPVP-gastropatiiakh. Lechebnoe delo. 2016; 3: 50–8 (in Russian).] 76. Yamamoto T, Isono A, Mishina Y et al. Gastroduodenal mucosal injury in patients taking low-dose aspirin and the role of gastric mucoprotective drugs: possible effect of rebamipide. J Clin Biochem Nutrition 2010; 47 (1): 27–31. 77. Ono S, Kato M, Imai A et al. Preliminary trial of rebamipide for prevention of low-dose aspirin-induced gastric injury in healthy subjects: a randomized, double-blind, placebo-controlled, cross-over study. J Clin Biochem Nutrition 2009; 45 (2): 248–53. 78. Tozawa K, Oshima T, Okugawa T et al. A randomized, double-blind, placebo-controlled study of rebamipide for gastric mucosal injury taking aspirin with or without clopidogrel. Dig Dis Scien 2014; 59: (8) 1885–90. 79. Watande N, Takeuchi T, Handa O et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate-to-severe small intestinal damage. PLoS one 2015; 10 (4): e0122330. 80. Kim JH, Park SH, Cho CS et al. Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory drug-induced mucosal toxicity. Gut Liver 2014; 8 (4): 371–9. 81. Боровкова Н.Ю., Буянова М.В., Бакка Т.Е. и др. Патогенетические подходы к лечению аспирининдуцированных гастроэнтеропатий при длительном приеме ацетилсалициловой кислоты у больных с хронической ишемической болезнью сердца. Терапия. 2020; 3 (37): 56–62. DOI 10.18565/therapy.2020.3.56-62 [Borovkova N.Iu., Buianova M.V., Bakka T.E. et al. Patogeneticheskie podkhody k lecheniiu aspirinindutsirovannykh gastroenteropatii pri dlitel'nom prieme atsetilsalitsilovoi kisloty u bol'nykh s khronicheskoi ishemicheskoi bolezn'iu serdtsa. Terapiia. 2020; 3 (37): 56–62. DOI 10.18565/therapy.2020.3.56-62 (in Russian).] 82. Takeshi Yamashita et al. Observational study of the effects of dabigatran on gastrointestinal symptoms in patients with non-valvular atrial fibrillation. J Arrhythmia 2014; 30 (December): 478–84.